Chordia Therapeutics (TSE:190A) Beneish M-Score: 0.00 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics Beneish M-Score?

Chordia Therapeutics TSE:190A -2.53% 11 Beneish M-Score is 0.00 as of Jul. 20, 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 825 Biotechnology companies, Chordia Therapeutics ranks worse than 121212% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Chordia Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 5 years, the highest Beneish M-Score of Chordia Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.

Chordia Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Beneish M-Score Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Beneish M-Score
0.00 0.00 0.00 0.00 0.00

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Beneish M-Score Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

TSE:190A vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Chordia Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chordia Therapeutics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's Beneish M-Score falls into.


TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Chordia Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Aug25) TTM:Last Year (Aug24) TTM:
Total Receivables was 円0.00 Mil.
Revenue was 円0.00 Mil.
Gross Profit was 円-1,425.31 Mil.
Total Current Assets was 円2,669.03 Mil.
Total Assets was 円2,681.35 Mil.
Property, Plant and Equipment(Net PPE) was 円0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was 円2.70 Mil.
Selling, General, & Admin. Expense(SGA) was 円0.00 Mil.
Total Current Liabilities was 円244.34 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.00 Mil.
Net Income was 円-1,785.87 Mil.
Gross Profit was 円0.00 Mil.
Cash Flow from Operations was 円-1,836.92 Mil.
 Total Receivables was 円0.00 Mil.
Revenue was 円0.00 Mil.
Gross Profit was 円-1,499.80 Mil.
Total Current Assets was 円4,605.42 Mil.
Total Assets was 円4,632.37 Mil.
Property, Plant and Equipment(Net PPE) was 円2.74 Mil.
Depreciation, Depletion and Amortization(DDA) was 円4.10 Mil.
Selling, General, & Admin. Expense(SGA) was 円0.00 Mil.
Total Current Liabilities was 円471.07 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0) / (0 / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-1499.795 / 0) / (-1425.309 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2669.033 + 0) / 2681.349) / (1 - (4605.418 + 2.744) / 4632.37)
=0.004593 / 0.005226
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.095 / (4.095 + 2.744)) / (2.702 / (2.702 + 0))
=0.598772 / 1
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 0) / (0 / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 244.338) / 2681.349) / ((0 + 471.072) / 4632.37)
=0.091125 / 0.101691
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1785.867 - 0 - -1836.921) / 2681.349
=0.01904

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Chordia Therapeutics (TSE:190A) has a Beneish M-Score of 0.00 as of Jul. 20, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Chordia Therapeutics and its competitors. According to the industry distribution chart, Chordia Therapeutics ranks #999999 out of 825 companies in the Biotechnology industry.
Is Chordia Therapeutics' Beneish M-Score too high?
Chordia Therapeutics' current Beneish M-Score is 0.00. Based on the distribution chart, Chordia Therapeutics ranks #999999 out of 825 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chordia Therapeutics ranks #999999 out of 825 companies for Beneish M-Score. This places Chordia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Beneish M-Score is 0.00 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price